Compass Diversified Unit Altor Solutions to Acquire Lifoam Industries for $137 Million-February 2024-www.financetom.com

Compass Diversified Unit Altor Solutions to Acquire Lifoam Industries for $137 Million

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Compass Diversified Unit Altor Solutions to Acquire Lifoam Industries for $137 Million

Aug 19, 2024 5:53 AM

08:39 AM EDT, 08/19/2024 (MT Newswires) -- Compass Diversified ( CODI ) subsidiary Altor Solutions said Monday it has agreed to acquire Lifoam Industries, a temperature-controlled shipping services manufacturer, for $137 million in cash.

Altor said the deal will boost its cold-chain packaging capabilities and expand its customer base.

The deal is expected to close in September, Altor said.

Previous page： European major satellite venture still needs some time to finalise, source says Next page： Alvotech, Advanz Pharma Say Europe Accepts Marketing Application for Asthma Drug Biosimilar

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

European major satellite venture still needs some time to finalise, source says

Oct 6, 2025

ROME/PARIS, Oct 6 (Reuters) - A framework agreement between France's Airbus and Thales and Italy's Leonardo to create a major new European satellite manufacturer will still require some weeks, a source told Reuters on Monday. The person familiar with the matter said key details remain under discussion and that the boards of the three companies are working to reach a...

Alvotech, Advanz Pharma Say Europe Accepts Marketing Application for Asthma Drug Biosimilar

Oct 6, 2025

05:20 AM EDT, 10/06/2025 (MT Newswires) -- Alvotech ( ALVO ) and Advanz Pharma said Monday that the European Medicines Agency has accepted a marketing authorization application for AVT23, a proposed biosimilar to Xolair, or omalizumab, a drug used to control allergy-related asthma. The drug is also used to treat long-term itchy rash and inflamed lining of the nose and...

Oculis to Advance Privosegtor to Registrational Trials for Neuro-Ophthalmology Indications

Oct 6, 2025

04:54 AM EDT, 10/06/2025 (MT Newswires) -- Oculis Holding ( OCS ) said Monday it is advancing its Privosegtor product candidate to a registrational program for neuro-ophthalmology indications following a positive meeting with the US Food and Drug Administration. The company plans to start the program this year, with three trials to support the registration process. The first trial is...

Danaos Plans $500 Million Private Debt Offering; Shares Up Pre-Bell

Oct 6, 2025

05:17 AM EDT, 10/06/2025 (MT Newswires) -- Danaos ( DAC ) said Monday it plans a private offering of up to $500 million of senior notes due 2032, subject to market conditions and other factors. The company intends to use the net proceeds to fully redeem the $262.8 million outstanding principal amount of its 8.5% senior notes due 2028 on...